Many of you, as retina specialists, support colleagues from other ophthalmic specialties while maintaining your own growing IVI workload. Taking a break is not an option.
Real-world studies around the globe show that less than 7% of patients never miss an injection and only 38% still come at all after 2 years*.
*Sources: PERSEUS study, Eter 2021, n=803 / Medicare review, Lad 2014, n=459,237
You often encounter the need for manual entries into practice systems due to incompatibilities between devices. Some of you have mentioned feeling more like IT managers rather than clinicians.
deepeye® TPS* provides an expert-level 2nd opinion based on tens of thousands of similar cases, treated with exceptional results. Besides disease activity level, the software also highlights maximum IRF/SRF/PED areas.
deepeye® TPS* provides for the 1st time a prediction of the individual patient’s response to treatment and the expected treatment need over the coming 12 months (# if IVIs).
deepeye® TPS* processes scans from 10+ common OCT devices (HE, ZEISS, Topcon ...) and works with ophthalmic imaging software like HE Heyex 2 and in the future also Zeiss Forum and Topcon Harmony.
* CE marking pending. deepeye® TPS is a medical device that may present potential risks as a treatment planning aid for patients with nAMD. For comprehensive safety information, please consult the electronic instructions for use.
▫️ 24/7 expert assistance for every clinician in IVI decision making
▫️shorten / extend interval (T&E)
▫️or inject / wait (PRN).
▫️ Available across your network.
Educate patients easily & integrated into your IVI process to drive adherence and persistence.
Answer patients’ most frequently asked question: “What happens next?”
One AI solution for supporting your IVI process including referring doctors.
Your medical assistants generate AI reports with just 1 click.
Initiated by doctors for doctors, here’s what users of deepeye TPS say about us.
"For the first time, the deepeye solution enables a needs-oriented, patient-specific treatment strategy."
"I don’t need AI to recognize AMD.
I need deepeye to predict my patients’ disease progression."
”The first deepeye analyses of DME make me confident that, after AMD patients, we can also use this great tool for diabetics.”
